The Early Advantage For IND Success And Beyond

An IND submission requires manufacturing information on composition, manufacturer, stability, controls, and the ability to supply consistent batches. The choices behind that information rarely stay confined to the filing. They carry into cGMP operations and ultimately influence whether a pipeline is commercially viable.

Written by Hadrien Piana, Director, Strategic Marketing at Lonza Cell and Gene, this white paper considers how early decisions can be made with later outcomes in mind, and why timeline promises deserve scrutiny when funding milestones create pressure to move fast. It surveys dedicated bench-to-IND pathways across autologous and allogeneic CAR-T, NK cells, EVs, MSCs, hPSCs, AAV, and lentiviral vectors, with platform details specific to each.

Explore the paper to see how each modality's path to the clinic is structured.